ELSEVIER

Psychiatry Research: Neuroimaging 68 (1997) 185–186

PSYCHIATRY
RESEARCH
NEUROIMAGING

Author Index for 1996

Abraham, H.D., **67**:173
Ågren, H., **67**:1
Alpert, M., **67**:59
Amering, M., **68**:41
Andreasen, N.C., **67**:145
Antoni, G., **67**:1
Arndt, S., **67**:145
Asenbaum, S., **68**:23
Aylward, E.H., **68**:65

Badawi, R., **68**:111
Baischer, W., **68**:41
Bakish, D., **68**:31
Barkely, J., **68**:31
Barta, P.E., **67**:155, **68**:65
Bartels, M., **67**:135
Bartzokis, G., **67**:189
Becker, T., **67**:135
Beckmann, H., **67**:135, **68**:87, **68**:99
Berger, P., **68**:41
Biersack, H.-J., **68**:1
Black, K.J., **67**:203
Bookstein, F.L., **67**:81
Bormans, G., **68**:11
Boyko, O.B., **67**:215, **68**:55
Branchey, M., **67**:39
Brodaty, H., **68**:133
Brücke, T., **68**:23
Brunberg, J.A., **67**:81
Brunsden, B.S., **67**:203
Bubeck, B., **68**:125
Bucci, P., **67**:113
Buckley, P.F., **67**:123
Buydens-Branchey, L., **67**:39
Byrum, C.E., **67**:215

Challakere, K., **67**:99
Charles, H.C., **67**:215
Chase, G.A., **68**:65
Chasten, K., **67**:39
Chitilla, V.R., **67**:215
Christensen, G.E., **67**:203
Cizadlo, T., **67**:145
Compton-Toth, B., **67**:17
Danos, P., **68**:1
Dantendorfer, K., **68**:41
Davidson, P.B., **67**:59
De Groot, T., **68**:11
Demisch, S., **68**:125
DeQuardo, J.R., **67**:81
Dery, K., **67**:189
Donovan, B., **67**:17
Downhill, J., **67**:145
Duffy, F.H., **67**:173
Dupont, P., **68**:11
Dupont, R.M., **67**:99

Elkis, H., **67**:123
Elmer, K., **67**:135
Farde, L., **67**:161, **67**:163

Fasth, K.J., **67**:1
Fenton, G.W., **68**:111
Fenwick, P.B.C., **68**:111
Fowler, J.S., **67**:11
Frazier, J.A., **68**:77
Friedman, L., **67**:123

Gado, M.H., **67**:203
Galderisi, S., **67**:113
Garada, B., **67**:59
Garnett, M.L., **67**:17
Gatley, S.J., **67**:11
Gaur, R., **68**:133
Giedd, J.N., **68**:77
Gillespie, H., **67**:29
Gjedde, A., **67**:159
Gössler, R., **68**:23
Goyer, P.F., **67**:17
Grant, C., **67**:29
Grant, I., **67**:99
Green, W.D.K., **67**:81
Grodd, W., **67**:135
Grünwald, F., **68**:1

Haindl, W., **68**:133
Halldin, C., **67**:163
Halpern, S., **67**:99
Hamburger, S.D., **68**:77
Harris, G.J., **68**:65
Hartvig, P., **67**:1
Heckers, S., **67**:135
Higashima, M., **67**:49
Hisada, K., **67**:49
Hitzemann, R., **67**:11
Hollister, L., **67**:29
Holman, B.L., **67**:59

Iidaka, T., **68**:143
Imhof, H., **68**:41
Itoh, M., **67**:71

Jacobsen, L.K., **68**:77

Kasper, S., **68**:1, **68**:23
Katschnig, H., **68**:41
Kaufman, B., **67**:123
Kawasaki, Y., **67**:49
Kim, D., **67**:215
Klemm, E., **68**:1
Knott, V.J., **68**:31
Koder, D., **68**:133
Koshino, Y., **67**:49
Kramer, J., **68**:41
Krishnan, K.R.R., **67**:215, **68**:55
Küfferle, B., **68**:23

Laack, K., **67**:189
Lamoureux, G., **67**:99
Långström, B., **67**:1
Lauer, M., **68**:87, **68**:99
Lee, H.S., **67**:123
Lehr, P.P., **67**:99
Leisure, G., **67**:17
Lenane, M.C., **68**:77
Lewis, P., **68**:111
Lin, D.Y., **67**:203
Lindström, L., **67**:1
Logan, J., **67**:11
Lumsden, J., **68**:111
Lundberg, T., **67**:1
Lundqvist, H., **67**:1
Lusk-Mikkelsen, S., **68**:31
Lys, C., **67**:123

Maayan, M.L., **67**:39
MacFall, J.R., **67**:215
MacGregor, R.R., **67**:11
Maeda, Y., **67**:49
Maehara, T., **68**:143

Maes, M., **68**:11
Maisey, M.N., **68**:111
Maj, M., **67**:113
Marder, S.R., **67**:189
Matsuda, H., **67**:49, **68**:143
Matsui, H., **67**:71
McCormick, R., **67**:17
McDonald, W.M., **68**:55
Meares, S., **68**:133
Meguro, K., **67**:71
Meltzer, H.Y., **67**:123
Mignone, M.L., **67**:113
Mintz, J., **67**:189
Miraldi, F., **67**:17
Möller, H.-J., **68**:1
Morris, E., **67**:17
Mortelmans, L., **68**:11
Mucci, A., **67**:113
Mullani, N., **67**:29
Muswick, G., **67**:17

Nakajima, T., **68**:143
Nelson, D., **67**:17
Nordström, A.-L., **67**:161
Nuechterlein, K.H., **67**:189
Nyberg, S., **67**:163

O'Leary, D., **67**:145
Okazaki, A., **68**:143

Passe, T., **67**:215
Pearlson, G.D., **67**:155, **68**:65
Perugini, M., **68**:31
Peuskens, J., **68**:11
Podreka, I., **68**:23
Powers, R.E., **67**:155, **68**:65
Prayer, D., **68**:41

Rabins, P.V., **68**:65
Rajagopalan, P., **67**:215
Rajapakse, J.C., **68**:77
Rajarethinam, R., **67**:145
Rapoport, J.L., **68**:77
Reed, R.J., **67**:99
Reibring, L., **67**:1
Reith, J., **67**:159
Rose, J.S., **67**:39
Rosier, A., **68**:11
Rourke, S.B., **67**:99

Sachdev, P., **68**:133
Sakai, N., **67**:49
Sasaki, H., **67**:71
Sauer, H., **68**:125
Schiepers, C., **68**:11
Schildkraut, J.J., **67**:59
Schlyer, D.J., **67**:11
Schneider, F., **67**:135
Schneider, M., **67**:135
Schoder, M., **68**:41
Schröder, J., **68**:125
Schulz, S.C., **67**:17
Schwartz, R.B., **67**:59
Semple, W.E., **67**:17
Sharkoff, J., **67**:17
Sheline, Y.I., **67**:203
Shiraishi, H., **68**:143
Smith, J.S., **67**:215
Stapleton, J.M., **67**:39
Steffens, D.C., **68**:55
Steinberger, K., **68**:41
Suzuki, M., **67**:49
Suzuki, Y., **68**:143

Tancredi, L., **67**:29
Tandon, R., **67**:81
Tauscher, J., **68**:23
Tien, A.Y., **67**:155
Topitz-Schratzberger, A., **68**:23
Tune, L.E., **67**:155, **68**:65
Tupler, L.A., **68**:55

Upchurch, L., **67**:215

Vaituzis, A.C., **68**:77
Valentine, A., **67**:29
Vandenberghe, R., **68**:11
Vannier, M.W., **67**:203
Vasile, R.G., **67**:59
Verbruggen, A., **68**:11
Vesely, C., **68**:23
Volkow, N.D., **67**:11, **67**:29

Wagner, H.N., **67**:155
Walker, A., **68**:133
Wang, G.-J., **67**:11
Werrell, A., **67**:39
Windhaber, J., **68**:41
Wolf, A.P., **67**:11
Wong, D., **67**:155, **67**:159
Wong, M.T.H., **68**:111

Xanthakos, S., **67**:215

Yamaguchi, N., **67**:49
Yamaguchi, S., **67**:71
Yamaguchi, T., **67**:71
Yamazaki, H., **67**:71

UMI

SHOULD READ SUBJECT INDEX 1996-1997

ELSEVIER

Psychiatry Research: Neuroimaging 68 (1997) 187–202

PSYCHIATRY RESEARCH NEUROIMAGING

Subject index for 1996

Affective disorder
age, frontal cortex, **67**:59
age, single photon emission computed tomography, **67**:59
age, temporal lobe, **67**:59
cerebral blood flow, frontal lobe, **68**:143
computed tomography, frontal lobe, sulcal prominence, **67**:123
computed tomography, ventricle-brain ratio, **67**:123
frontal lobe, age, **67**:59
frontal lobe, computed tomography, **67**:123
frontal lobe, geriatric depression, **67**:59
frontal lobe, single photon emission computed tomography, **67**:59, **68**:1, **68**:143
geriatric depression, frontal cortex, **67**:59
geriatric depression, single photon emission computed tomography, **67**:59
geriatric depression, temporal lobe, **67**:59
major depression, computed tomography, **67**:123
major depression, frontal cortex, **67**:123
major depression, sulcal prominence, **67**:123
major depression, ventricle-brain ratio, **67**:123
single photon emission computed tomography, age, **67**:59
single photon emission computed tomography, frontal lobe, **67**:59, **68**:1, **68**:143
single photon emission computed tomography, geriatric depression, **67**:59
single photon emission computed tomography, temporal lobe, **67**:59, **68**:1
sulcal prominence, computed tomography, **67**:123
temporal lobe, age, **67**:59
temporal lobe, geriatric depression, **67**:59
temporal lobe, single photon emission computed tomography, **67**:59, **68**:1
unipolar subtype, computed tomography, **67**:123
unipolar subtype, frontal cortex, **67**:123
unipolar subtype, sulcal prominence, **67**:123
unipolar subtype, ventricle-brain ratio, **67**:123
ventricle-brain ratio, computed tomography, **67**:123

Age
Alzheimer's Disease, cognitive impairment, magnetic resonance imaging, **68**:65
Alzheimer's Disease, temporal lobe, **68**:65
affective disorder, frontal cortex, **67**:59
affective disorder, single photon emission computed tomography, **67**:59
affective disorder, temporal lobe, **67**:59
altanserin, positron emission tomography, **68**:11
altanserin, receptor loss with age, **68**:11
altanserin, serotonin, **68**:11
basal ganglia, iron content, **68**:55
basal ganglia, magnetic resonance imaging, **68**:55
cerebellum, multi-infarct dementia, **67**:71
cerebellum, positron emission tomography, **67**:71
cerebellum, wandering behavior, **67**:71
dementia, cerebellum, **67**:71
dementia, frontal cortex, **67**:71
dementia, positron emission tomography, **67**:71
dementia, wandering behavior, **67**:71
dopamine, receptor binding, striatum, **67**:11
frontal cortex, affective disorder, **67**:59
frontal cortex, dementia, **67**:71
frontal cortex, geriatric depression, **67**:59
frontal cortex, multi-infarct dementia, **67**:71
frontal cortex, positron emission tomography, **67**:71
frontal cortex, single photon emission computed tomography, **67**:59
frontal cortex, wandering behavior, **67**:71
geriatric depression, frontal cortex, **67**:59
geriatric depression, single photon emission computed tomogrphy, **67**:59
geriatric depression, temporal lobe, **67**:59
globus pallidus, magnetic resonance imaging, **68**:55
iron content, basal ganglia, **68**:55
iron content, magnetic resonance imaging, **68**:55
magnetic resonance imaging, basal ganglia, **68**:55
magnetic resonance imaging, globus pallidus, **68**:55
magnetic resonance imaging, iron content, **68**:55
magnetic resonance imaging, putamen, **68**:55
magnetic resonance imaging, schizophrenia, **67**:189
magnetic resonance imaging, temporal lobe, **67**:189
multi-infarct dementia, cerebellum, **67**:71
multi-infarct dementia, frontal cortex, **67**:71
multi-infarct dementia, positron emission tomography, **67**:71
multi-infarct dementia, wandering behavior, **67**:71
positron emission tomography, altanserin, **68**:11
positron emission tomography, cerebellum, **67**:71
positron emission tomography, dementia, **67**:71

positron emission tomography, dopamine, **67**:11
positron emission tomography, frontal cortex, **67**:71
positron emission tomography, methylspiroperidol, **67**:11
positron emission tomography, multi-infarct dementia, **67**:71
positron emission tomography, raclopride, **67**:11
positron emission tomography, receptor binding, **67**:11, **68**:11
positron emission tomography, receptor loss with age, **68**:11
positron emission tomography, serotonin, **68**:11
positron emission tomography, striatum, **67**:11
positron emission tomography, wandering behavior, **67**:71
putamen, magnetic resonance imaging, **68**:55
raclopride, dopamine, **67**:11
raclopride, positron emission tomography, **67**:11
raclopride, receptor binding, **67**:11
raclopride, striatum, **67**:11
receptor binding, altanserin, **68**:11
receptor binding, dopamine, **67**:11
receptor binding, methylspiroperidol, **67**:11
receptor binding, positron emission tomography, **67**:11, **68**:11
receptor binding, raclopride, **67**:11
receptor binding, serotonin, **68**:11
receptor binding, striatum, **67**:11
receptor loss with age, positron emission tomography, **68**:11
schizophrenia, age of onset, **67**:189
schizophrenia, late age of onset, magnetic resonance imaging, **68**:65
schizophrenia, magnetic resonance imaging, **67**:189, **68**:65
schizophrenia, temporal lobe, **67**:189, **68**:65
serotonin, positron emission tomography, **68**:11
serotonin, receptor binding, **68**:11
serotonin, receptor loss with age, **68**:11
single photon emission computed tomography, affective disorder, **67**:59
single photon emission computed tomography, frontal cortex, **67**:59
single photon emission computed tomography, geriatric depression, **67**:59
single photon emission computed tomography, temporal lobe, **67**:59
striatum, dopamine, **67**:11
striatum, methylspiroperidol, **67**:11
striatum, positron emission tomography, **67**:11
striatum, raclopride, **67**:11
temporal lobe, affective disorder, **67**:59
temporal lobe, age of onset, **67**:189
temporal lobe, Alzheimer's Disease, **68**:65
temporal lobe, geriatric depression, **67**:59
temporal lobe, magnetic resonance imaging, **67**:189, **68**:65
temporal lobe, schizophrenia, **67**:189, **68**:65
temporal lobe, single photon emission computed tomography, **67**:59
temporal lobe length, magnetic resonance imaging, **67**:189
wandering behavior, cerebellum, **67**:71
wandering behavior, frontal cortex, **67**:71
wandering behavior, multi-infarct dementia, **67**:71
wandering behavior, positron emission tomography, **67**:71

Alcohol abuse/dependence. *See also* Substance abuse/dependence

abstinence, neuropsychology, **67**:99
abstinence, Raven's progressive-matrices, **67**:99
abstinence, single photon emission computed tomography, **67**:99
iodoamphetamine, single photon emission computed tomography, **67**:99
neuropsychology, abstinence, **67**:99
neuropsychology, single photon emission computed tomography, **67**:99
Raven's progressive-matrices, abstinence, **67**:99
Raven's progressive-matrices, single photon emission computed tomography, **67**:99
single photon emission computed tomography, abstinence, **67**:99
single photon emission computed tomography, iodoamphetamine, **67**:99
single photon emission computed tomography, neuropsychology, **67**:99
single photon emission computed tomography, Raven's progressive-matrices, **67**:99
single photon emission computed tomography, smoking, **67**:99
smoking, single photon emission computed tomography, **67**:99

Alzheimer's Disease

cerebral blood flow, longitudinal course, **68**:133
cerebral blood flow, neuropsychological tests, **68**:133
cognitive impairment, magnetic resonance imaging, **68**:65
longitudinal course, cerebral blood flow, **68**:133
longitudinal course, neuropsychological tests, **68**:133
longitudinal course, single photon emission computed tomography, **68**:133
magnetic resonance imaging, volumetry, **68**:65
magnetic resonance imaging, temporal lobe, **68**:65
neuropsychological tests, cerebral blood flow, **68**:133
neuropsychological tests, longitudinal course, **68**:133
neuropsychological tests, single photon emission computed tomography, **68**:133
single photon emission computed tomography, longitudinal course, **68**:133
single photon emission computed tomography, neuropsychological tests, **68**:133
single photon emission computed tomography, Tc-hexamethy propyleneamine oxime, **68**:133
temporal lobe, magnetic resonance imaging, **68**:65

Anxiety

electroencephalography, magnetic resonance imaging, **68**:41
electroencephalography, panic disorder, **68**:31, **68**:41
electroencephalography, topographic mapping, **68**:31
magnetic resonance imaging, electroencephalography, **68**:41
magnetic resonance imaging, panic disorder, **68**:41
magnetic resonance imaging, septohippocampal system, **68**:41
panic disorder, electroencephalography, **68**:31, **68**:41
panic disorder, magnetic resonance imaging, **68**:41
panic disorder, septohippocampal system, **68**:41

septohippocampal system, magnetic resonance imaging, **68**:41
septohippocampal system, panic disorder, **68**:41

Attention

continuous performance test, parietal cortex, positron emission tomography, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
continuous performance test, substance abuse, **67**:17
parietal cortex, continuous performance test, **67**:17
parietal cortex, positron emission tomography, **67**:17
parietal cortex, posttraumatic stress disorder, **67**:17
parietal cortex, substance abuse, **67**:17
positron emission tomography, continuous performance test, **67**:17
positron emission tomography, parietal cortex, **67**:17
positron emission tomography, posttraumatic stress disorder, **67**:17
positron emission tomography, substance abuse, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, parietal cortex, positron emission tomography, **67**:17
substance abuse, continuous performance test, **67**:17
substance abuse, parietal cortex, positron emission tomography, **67**:17

Basal ganglia *See also* Striatum

age, magnetic resonance imaging, **68**:55
dopamine, iodobenzamide, **68**:23
dopamine, obsessive-compulsive disorder, **68**:23
dopamine, psychotic patients, **68**:23
dopamine, receptor binding, **68**:23
dopamine, risperidone, **68**:23
dopamine, schizophrenia, **68**:23
dopamine, single photon emission computed tomography, **68**:23
globus pallidus, age, **68**:55
globus pallidus, magnetic resonance imaging, **68**:55
iodobenzamide, dopamine, **68**:23
iodobenzamide, obsessive-compulsive disorder, **68**:23
iodobenzamide, psychotic patients, **68**:23
iodobenzamide, receptor binding, **68**:23
iodobenzamide, risperidone, **68**:23
iodobenzamide, schizophrenia, **68**:23
iodobenzamide, single photon emission computed tomography, **68**:23
iron content, magnetic resonance imaging, **68**:55
magnetic resonance imaging, age, **68**:55
magnetic resonance imaging, globus pallidus, **68**:55
magnetic resonance imaging, iron content, **68**:55
magnetic resonance imaging, putamen, **68**:55
marijuana intoxication, positron emission tomography, **67**:29
obsessive-compulsive disorder, dopamine, **68**:23
obsessive-compulsive disorder, iodobenzamide, **68**:23
obsessive-compulsive disorder, risperidone, **68**:23
obsessive-compulsive disorder, single photon emission computed tomography, **68**:23
positron emission tomography, fluorodeoxyglucose, **67**:29
positron emission tomography, marijuana intoxication, **67**:29
positron emission tomography, substance abuse, **67**:29
positron emission tomography, tetrahydrocannabinol, **67**:29
psychotic patients, dopamine, **68**:23
psychotic patients, iodobenzamide, **68**:23
psychotic patients, risperidone, **68**:23
psychotic patients, single photon emission computed tomography, **68**:23
putamen, age, **68**:55
putamen, magnetic resonance imaging, **68**:55
receptor binding, dopamine, **68**:23
receptor binding, iodobenzamide, **68**:23
receptor binding, obsessive-compulsive disorder, **68**:23
receptor binding, psychotic patients, **68**:23
receptor binding, risperidone, **68**:23
receptor binding, schizophrenia, **68**:23
receptor binding, single photon emission computed tomography, **68**:23
risperidone, iodobenzamide, **68**:23
risperidone, obsessive-compulsive disorder, **68**:23
risperidone, psychotic patients, **68**:23
risperidone, receptor binding, **68**:23
risperidone, schizophrenia, **68**:23
risperidone, single photon emission computed tomography, **68**:23
schizophrenia, dopamine, **68**:23
schizophrenia, iodobenzamide, **68**:23
schizophrenia, receptor binding, **68**:23
schizophrenia, risperidone, **68**:23
schizophrenia, single photon emission computed tomography, **68**:23
single photon emission computed tomography, dopamine, **68**:23
single photon emission computed tomography, iodobenzamide, **68**:23
single photon emission computed tomography, obsessive-compulsive disorder, **68**:23
single photon emission computed tomography, psychotic patients, **68**:23
single photon emission computed tomography, receptor binding, **68**:23
single photon emission computed tomography, risperidone, **68**:23
single photon emission computed tomography, schizophrenia, **68**:23
substance abuse, positron emission tomography, **67**:29
tetrahydrocannabinol, positron emission tomography, **67**:29

Benzodiazepine

diazepam binding, frontal lobe, **68**:125
diazepam binding, schizophrenia, **68**:125
diazepam binding, single photon emission computed tomography, **68**:125
frontal lobe, diazepam binding, **68**:125
frontal lobe, schizophrenia, **68**:125
frontal lobe, single photon emission computed tomography, **68**:125

single photon emission computed tomography, diazepam binding, **68**:125
single photon emission computed tomography, schizophrenia, **68**:125
schizophrenia, diazepam binding, **68**:125
schizophrenia, frontal lobe, **68**:125
schizophrenia, single photon emission computed tomography, **68**:125

Cerebellum

age, multi-infarct dementia, **67**:71
age, positron emission tomography, **67**:71
age, wandering behavior, **67**:71
dementia, multi-infarct, **67**:71
dementia, positron emission tomography, **67**:71
dementia, wandering behavior, **67**:71
marijuana intoxication, positron emission tomography, **67**:29
multi-infarct dementia, age, **67**:71
multi-infarct dementia, positron emission tomography, **67**:71
multi-infarct dementia, wandering behavior, **67**:71
positron emission tomography, age, **67**:71
positron emission tomography, dementia, **67**:71
positron emission tomography, fluorodeoxyglucose, **67**:29, **67**:71
positron emission tomography, marijuana intoxication, **67**:29
positron emission tomography, multi-infarct dementia, **67**:71
positron emission tomography, substance abuse, **67**:29
positron emission tomography, tetrahydrocannabinol, **67**:29
positron emission tomography, wandering behavior, **67**:71
substance abuse, positron emission tomography, **67**:29
tetrahydrocannabinol, positron emission tomography, **67**:29
wandering behavior, age, **67**:71
wandering behavior, multi-infarct dementia, **67**:71
wandering behavior, positron emission tomography, **67**:71

Cerebral blood flow. See also Single photon emission computed tomography, Positron emission tomography

affective disorder, frontal lobe, **68**:143
Alzheimer's Disease, longitudinal course, **68**:133
Alzheimer's Disease, neuropsychological tests, **68**:133
attention, parietal cortex, **67**:17
attention, posttraumatic stress disorder, **67**:17
attention, substance abuse, **67**:17
continuous performance test, parietal cortex, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
continuous performance test, substance abuse, **67**:17
frontal lobe, affective disorder, **68**:143
neuropsychological tests, Alzheimer's Disease, **68**:133
parietal cortex, attention, **67**:17
parietal cortex, continuous performance test, **67**:17
parietal cortex, posttraumatic stress disorder, **67**:17
parietal cortex, substance abuse, **67**:17
posttraumatic stress disorder, attention, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, parietal cortex, **67**:17
substance abuse, attention, **67**:17
substance abuse, continuous performance test, **67**:17
substance abuse, parietal cortex, **67**:17

Childhood schizophrenia

corpus callosum, magnetic resonance imaging, **68**:77
white matter sparing, magnetic resonance imaging, **68**:77

Clozapine

dopamine, frontal cortex, **67**:1
dopamine, positron emission tomography, **67**:1
dopamine, receptor binding, **67**:1
dopamine, striatum, **67**:1
electroencephalography, healthy subjects, **67**:113
electroencephalography, multilead mapping, **67**:113
frontal cortex, dopamine, **67**:1
frontal cortex, positron emission tomography, **67**:1
frontal cortex, receptor binding, **67**:1
frontal cortex, serotonin, **67**:1
healthy subjects, electroencephalographic brain mapping, **67**:113
healthy subjects, pharmaco-electroencephalography, **67**:113
pharmaco-electroencephalography, healthy subjects, **67**:113
positron emission tomography, dopamine, **67**:1
positron emission tomography, frontal cortex, **67**:1
positron emission tomography, receptor binding, **67**:1
positron emission tomography, serotonin, **67**:1
positron emission tomography, striatum, **67**:1
receptor binding, dopamine, **67**:1
receptor binding, frontal cortex, **67**:1
receptor binding, positron emission tomography, **67**:1
receptor binding, serotonin, **67**:1
receptor binding, striatum, **67**:1
serotonin, frontal cortex, **67**:1
serotonin, positron emission tomography, **67**:1
serotonin, receptor binding, **67**:1
striatum, dopamine, **67**:1
striatum, positron emission tomography, **67**:1
striatum, receptor binding, **67**:1

Computed tomography

affective disorder, frontal cortex, **67**:123
affective disorder, sulcal prominence, **67**:123
affective disorder, ventricle-brain ratio, **67**:123
frontal cortex, affective disorder, **67**:123
frontal cortex, schizophrenia, **67**:123
schizophrenia, frontal cortex, **67**:123
schizophrenia, sulcal prominence, **67**:123
schizophrenia, ventricle-brain ratio, **67**:123
sulcal prominence, affective disorder, **67**:123
sulcal prominence, schizophrenia, **67**:123
ventricle-brain ratio, affective disorder, **67**:123
ventricle-brain ratio, schizophrenia, **67**:123

Corpus callosum

age, childhood onset schizophrenia, **68**:77
childhood schizophrenia, magnetic resonance imaging, **68**:77
magnetic resonance imaging, childhood schizophrenia, **68**:77
magnetic resonance imaging, schizophrenia, **67**:81, **68**:77

magnetic resonance imaging, shape analysis, **67**:81
schizophrenia, childhood onset, **68**:77
schizophrenia, magnetic resonance imaging, **67**:81, **68**:77

Dementia. *See also* Alzheimer's Disease
cerebellum, positron emission tomography, **67**:71
frontal cortex, positron emission tomography, **67**:71
frontal cortex, wandering behavior, **67**:71
multi-infarct, positron emission tomography, **67**:71
multi-infarct, wandering behavior, **67**:71
positron emission tomography, age, **67**:71
positron emission tomography, cerebellum, **67**:71
positron emission tomography, fluorodeoxyglucose, **67**:71
positron emission tomography, frontal cortex, **67**:71
positron emission tomography, multi-infarct, **67**:71
positron emission tomography, wandering behavior, **67**:71
wandering behavior, cerebellum, **67**:71
wandering behavior, frontal cortex, **67**:71
wandering behavior, positron emission tomography, **67**:71

Depression. *See* Affective disorder

Dopamine
age, methylspiroperidol, **67**:11
age, positron emission tomography, **67**:11
age, raclopride, **67**:11
age, receptor binding, **67**:11
age, striatum, **67**:11
basal ganglia, iodobenzamide, **68**:23
basal ganglia, obsessive-compulsive disorder, **68**:23
basal ganglia, psychotic patients, **68**:23
basal ganglia, receptor binding, **68**:23
basal ganglia, risperidone, **68**:23
basal ganglia, schizophrenia, **68**:23
basal ganglia, single photon emission computed tomography, **68**:23
clozapine, frontal cortex, **67**:1
clozapine, positron emission tomography, **67**:1
clozapine, receptor binding, **67**:1
clozapine, striatum, **67**:1
frontal cortex, clozapine, **67**:1
frontal cortex, positron emission tomography, **67**:1
frontal cortex, receptor binding, **67**:1
haloperidol, positron emission tomography, **67**:163
haloperidol, raclopride, **67**:163
haloperidol, receptor binding, **67**:163
haloperidol, schizophrenia, **67**:163
haloperidol, striatum, **67**:163
iodobenzamide, basal ganglia, **68**:23
iodobenzamide, obsessive-compulsive disorder, **68**:23
iodobenzamide, psychotic patients, **68**:23
iodobenzamide, receptor binding, **68**:23
iodobenzamide, risperidone, **68**:23
iodobenzamide, schizophrenia, **68**:23
iodobenzamide, single photon emission computed tomography, **68**:23
methylspiperone, positron emission tomography, **67**:159
methylspiperone, receptor binding, **67**:159
methylspiperone, schizophrenia, **67**:159
methylspiroperidol, age, **67**:11
methylspiroperidol, positron emission tomography, **67**:11
methylspiroperidol, raclopride, **67**:11
methylspiroperidol, receptor binding, **67**:11
methylspiroperidol, striatum, **67**:11
obsessive-compulsive disorder, basal ganglia, **68**:23
obsessive-compulsive disorder, iodobenzamide, **68**:23
obsessive-compulsive disorder, receptor binding, **68**:23
obsessive-compulsive disorder, risperidone, **68**:23
obsessive-compulsive disorder, single photon emission computed tomography, **68**:23
positron emission tomography, age, **67**:11
positron emission tomography, clozapine, **67**:1
positron emission tomography, frontal cortex, **67**:1
positron emission tomography, haloperidol, **67**:163
positron emission tomography, methylspiperone, **67**:159
positron emission tomography, methylspiroperidol, **67**:11
positron emission tomography, raclopride, **67**:11, **67**:163
positron emission tomography, receptor binding, **67**:1, **67**:11, **67**:155, **67**:159, **67**:163
positron emission tomography, schizophrenia, **67**:155, **67**:159, **67**:163
positron emission tomography, striatum, **67**:1, **67**:11, **67**:155, **67**:163
psychotic patients, basal ganglia, **68**:23
psychotic patients, iodobenzamide, **68**:23
psychotic patients, receptor binding, **68**:23
psychotic patients, risperidone, **68**:23
psychotic patients, single photon emission computed tomography, **68**:23
raclopride, age, **67**:11
raclopride, positron emission tomography, **67**:11, **67**:163
raclopride, receptor binding, **67**:11, **67**:163
raclopride, schizophrenia, **67**:163
raclopride, striatum, **67**:11, **67**:163
receptor binding, age, **67**:11
receptor binding, basal ganglia, **68**:23
receptor binding, clozapine, **67**:1
receptor binding, frontal cortex, **67**:1
receptor binding, haloperidol, **67**:163
receptor binding, iodobenzamide, **68**:23
receptor binding, methylspiperone, **67**:159
receptor binding, methylspiroperidol, **67**:11
receptor binding, obsessive-compulsive disorder, **68**:23
receptor binding, positron emission tomography, **67**:1, **67**:11, **67**:155, **67**:159, **67**:163
receptor binding, psychotic patients, **68**:23
receptor binding, raclopride, **67**:11, **67**:163
receptor binding, risperidone, **68**:23
receptor binding, schizophrenia, **67**:155, **67**:159, **67**:163, **68**:23
receptor binding, single photon emission computed tomography, **68**:23
receptor binding, striatum, **67**:1, **67**:11, **67**:155, **67**:163
risperidone, basal ganglia, **68**:23
risperidone, iodobenzamide, **68**:23
risperidone, obsessive-compulsive disorder, **68**:23
risperidone, psychotic patients, **68**:23

risperidone, receptor binding, **68**:23
risperidone, schizophrenia, **68**:23
risperidone, single photon emission computed tomography, **68**:23
schizophrenia, basal ganglia, **68**:23
schizophrenia, haloperidol, **67**:163
schizophrenia, iodobenzamide, **68**:23
schizophrenia, methylspiperone, **67**:159
schizophrenia, positron emission tomography, **67**:155, **67**:159, **67**:163
schizophrenia, raclopride, **67**:163
schizophrenia, receptor binding, **67**:155, **67**:159, **67**:163, **68**:23
schizophrenia, risperidone, **68**:23
schizophrenia, single photon emission computed tomography, **68**:23
schizophrenia, striatum, **67**:155, **67**:163
serotonin, receptor binding, **67**:1
single photon emission computed tomography, basal ganglia, **68**:23
single photon emission computed tomography, iodobenzamide, **68**:23
single photon emission computed tomography, obsessive-compulsive disorder, **68**:23
single photon emission computed tomography, psychotic patients, **68**:23
single photon emission computed tomography, receptor binding, **68**:23
single photon emission computed tomography, risperidone, **68**:23
single photon emission computed tomography, schizophrenia, **68**:23
striatum, age, **67**:11
striatum, clozapine, **67**:1
striatum, haloperidol, **67**:163
striatum, methylspiroperidol, **67**:11
striatum, positron emission tomography, **67**:1, **67**:11, **67**:155, **67**:163
striatum, raclopride, **67**:11, **67**:163
striatum, receptor binding, **67**:1, **67**:11, **67**:155, **67**:163
striatum, schizophrenia, **67**:155, **67**:163

Electroencephalography *See also* Evoked potentials
anxiety, multilead mapping, **68**:31
clozapine, healthy subjects, **67**:113
clozapine, multilead mapping, **67**:113
cortical disinhibition, hallucinogen, **67**:173
cortical disinhibition, lysergic acid diethylamide, **67**:173
cortical disinhibition, perceptual disorder, **67**:173
cortical disinhibition, substance abuse, **67**:173
hallucinogen, cortical disinhibition, **67**:173
hallucinogen, perceptual disorder, **67**:173
healthy subjects, clozapine, **67**:113
healthy subjects, multilead mapping, **67**:113
lysergic acid diethylamide, cortical disinhibition, **67**:173
lysergic acid diethylamide, perceptual disorder, **67**:173
panic disorder, multilead mapping, **68**:31
perceptual disorder, cortical disinhibition, **67**:173
perceptual disorder, hallucinogen, **67**:173
perceptual disorder, lysergic acid diethylamide, **67**:173
perceptual disorder, substance abuse, **67**:173
pharmaco-electroencephalography, clozapine, **67**:113
pharmaco-electroencephalography, healthy subjects, **67**:113
substance abuse, cortical disinhibition, **67**:173
substance abuse, hallucinogen, **67**:173
substance abuse, lysergic acid diethylamide, **67**:173
substance abuse, perceptual disorder, **67**:173

Evoked potentials
cortical disinhibition, hallucinogen, **67**:173
cortical disinhibition, lysergic acid diethylamide, **67**:173
hallucinogen, cortical disinhibition, **67**:173
hallucinogen, multilead mapping, **67**:173
hallucinogen, perceptual disorder, **67**:173
lysergic acid diethylamide, cortical disinhibition, **67**:173
lysergic acid diethylamide, multilead mapping, **67**:173
lysergic acid diethylamide, perceptual disorder, **67**:173
perceptual disorder, hallucinogen, **67**:173
perceptual disorder, lysergic acid diethylamide, **67**:173
substance abuse, hallucinogen, **67**:173
substance abuse, lysergic acid diethylamide, **67**:173

Frontal lobe
affective disorder, computed tomography, **67**:123
affective disorder, single photon emission computed tomography, **67**:59, **68**:1, **68**:143
affective disorder, sulcal prominence, **67**:123
affective disorder, age, **67**:59
age, affective disorder, **67**:59
age, positron emission tomography, **67**:71
age, single photon emission computed tomography, **67**:59
age, wandering behavior, **67**:71
benzodiazepine receptor distribution, schizophrenia, **68**:125
benzodiazepine receptor distribution, single photon emission tomography, **68**:125
clozapine, positron emission tomography, **67**:1
computed tomography, affective disorder, **67**:123
computed tomography, schizophrenia, **67**:123
computed tomography, sulcal prominence, **67**:123
dementia, multi-infarct, **67**:71
dementia, positron emission tomography, **67**:71
dementia, wandering behavior, **67**:71
diazepam binding, schizophrenia, **68**:125
diazepam binding, single photon emission computed tomography, **68**:125
dopamine, positron emission tomography, **67**:1
dopamine, receptor binding, **67**:1
geriatric depression, single photon emission computed tomography, **67**:59
magnetic resonance imaging, volumetry, **67**:203
major depression, computed tomography, **67**:123
major depression, sulcal prominence, **67**:123
multi-infarct dementia, positron emission tomography, **67**:71

multi-infarct dementia, wandering behavior, **67**:71
negative symptoms, single photon emission computed tomography, **67**:49, **68**:1
positive symptoms, schizophrenia, **67**:49, **68**:1
positive symptoms, single photon emission computed tomography, **67**:49, **68**:1
positron emission tomography, clozapine, **67**:1
positron emission tomography, multi-infarct dementia, **67**:71
positron emission tomography, wandering behavior, **67**:71
schizophrenia, benzodiazepine receptor distribution, **68**:125
schizophrenia, computed tomography, **67**:123
schizophrenia, diazepam binding, **68**:125
schizophrenia, negative symptoms, **67**:49, **68**:1
schizophrenia, positive symptoms, **67**:49, **68**:1
schizophrenia, single photon emission computed tomography, **67**:49, **68**:1, **68**:125
schizophrenia, sulcal prominence, **67**:123
serotonin, positron emission tomography, **67**:1
serotonin, receptor binding, **67**:1
single photon emission computed tomography, age, **67**:59
single photon emission computed tomography, affective disorder, **67**:59, **68**:1, **68**:143
single photon emission computed tomography, benzodiazepine receptor distribution, **68**:125
single photon emission computed tomography, diazepam binding, **68**:125
single photon emission computed tomography, geriatric depression, **67**:59
single photon emission computed tomography, negative symptoms, **67**:49, **68**:1
single photon emission computed tomography, positive symptoms, **67**:49, **68**:1
single photon emission computed tomography, schizophrenia, **67**:49, **68**:1, **68**:125
stereology, magnetic resonance imaging, **67**:203
sulcal prominence, affective disorder, **67**:123
sulcal prominence, computed tomography, **67**:123
sulcal prominence, schizophrenia, **67**:123
unipolar depression, computed tomography, **67**:123
volumetry, magnetic resonance imaging, **67**:203
volumetry, stereology, **67**:203
wandering behavior, multi-infarct dementia, **67**:71
wandering behavior, positron emission tomography, **67**:71

Globus pallidus

age, iron content, **68**:55
age, magnetic resonance imaging, **68**:55
iron content, age, **68**:55
iron content, magnetic resonance imaging, **68**:55
magnetic resonance imaging, age, **68**:55
magnetic resonance imaging, iron content, **68**:55

Haloperidol

dopamine, positron emission tomography, receptor binding, **67**:163
dopamine, schizophrenia, striatum, **67**:163
positron emission tomography, dopamine, raclopride, receptor binding, **67**:163
positron emission tomography, schizophrenia, striatum, **67**:163
raclopride, positron emission tomography, dopamine receptor binding, **67**:163
raclopride, schizophrenia, striatum, **67**:163
schizophrenia, dopamine, receptor binding, positron emission tomography, **67**:163
schizophrenia, raclopride, striatum, **67**:163
striatum, dopamine, receptor binding, positron emission tomography, **67**:163
striatum, schizophrenia, **67**:163

Limbic system

hippocampal formation, magnetic resonance imaging, **67**:135
hippocampal formation, negative symptoms, schizophrenia, **67**:135
magnetic resonance imaging, hippocampal formation, **67**:135
magnetic resonance imaging, negative symptoms, schizophrenia, **67**:135
magnetic resonance imaging, volumetry, **67**:135
schizophrenia, hippocampal formation, magnetic resonance imaging, **67**:135
schizophrenia, negative symptoms, **67**:135

Lysergic acid diethylamide

electroencephalography, cortical disinhibition, **67**:173
electroencephalographyic multilead mapping, perceptual disorder, **67**:173
evoked potentials, cortical disinhibition, **67**:173
evoked potentials, multilead mapping, **67**:173
evoked potentials, perceptual disorder, **67**:173
perceptual disorder, cortical disinhibition, **67**:173
perceptual disorder, electroencephalography, **67**:173
perceptual disorder, evoked potentials, **67**:173
substance abuse, electroencephalography, **67**:173

Magnetic resonance imaging

age, basal ganglia, **68**:55
age, globus pallidus, **68**:55
age, putamen, **68**:55
age, temporal lobe, **67**:189
age of onset, schizophrenia, **67**:189, **68**:77
Alzheimer's Disease, temporal lobe, **68**:65
anxiety, septohippocampal system, **68**:41
basal ganglia, age, **68**:55
basal ganglia, iron content, **68**:55
childhood schizophrenia, corpus callosum, **68**:77
corpus callosum, childhood schizophrenia, **68**:77
corpus callosum, morphometrics, **67**:81
corpus callosum, schizophrenia, **67**:81, **68**:77
corpus callosum, shape analysis, **67**:81
frontal lobe, stereology, **67**:203
frontal lobe, volumetry, **67**:203

globus pallidus, age, **68**:55
globus pallidus, iron content, **68**:55
hippocampal formation, limbic system, **67**:135
hippocampal formation, schizophrenia, **67**:135
hippocampal formation, temporal lobe, **67**:135
hippocampal formation, third ventricle, **67**:135
hippocampal formation, volumetry, **67**:135
iron content, basal ganglia, **68**:55
limbic system, hippocampal formation, **67**:135
limbic system, schizophrenia, **67**:135
limbic system, volumetry, **67**:135
morphometrics, corpus callosum, **67**:81
morphometrics, neuroanatomic landmarks, **67**:81, **67**:145
morphometrics, schizophrenia, **67**:81
morphometrics, shape analysis, **67**:81
neuroanatomic landmarks, image analysis, **67**:81
neuroanatomic landmarks, morphometrics, **67**:81, **67**:145
neuroanatomic landmarks, reliability, **67**:145
neuroanatomic landmarks, schizophrenia, **67**:81
panic disorder, septohippocampal system, **68**:41
putamen, age, **68**:55
putamen, iron content, **68**:55
schizophrenia, age, **67**:189
schizophrenia, age of onset, **67**:189, **68**:77
schizophrenia, childhood onset, corpus callosum, **68**:77
schizophrenia, corpus callosum, **67**:81, **68**:77
schizophrenia, hippocampal formation, **67**:135
schizophrenia, late onset, **68**:65
schizophrenia, limbic system, **67**:135
schizophrenia, morphometrics, **67**:81
schizophrenia, negative symptoms, **67**:135
schizophrenia, neuroanatomic landmarks, **67**:81
schizophrenia, striatum, **67**:155
schizophrenia, superior temporal gyrus, **67**:155
schizophrenia, temporal lobe, **67**:135, **67**:155, **67**:189, **68**:65
schizophrenia, third ventricle, **67**:135
schizophrenia, volumetry, **67**:135, **67**:155, **68**:65
segmentation, methodology, **67**:215
segmentation, reliability, **67**:215
septohippocampal system, anxiety, **68**:41
septohippocampal system, panic disorder, **68**:41
stereology, methodology, **67**:203, **67**:215
stereology, reliability, **67**:203, **67**:215
striatum, schizophrenia, **67**:155
striatum, volumetry, **67**:155
superior temporal gyrus, schizophrenia, **67**:155
superior temporal gyrus, volumetry, **67**:155
temporal lobe, age, **67**:189
temporal lobe, age of onset of schizophrenia, **67**:189
temporal lobe, late-onset schizophrenia, **68**:65
temporal lobe, schizophrenia, **67**:135, **67**:155, **67**:189, **67**:189, **68**:65
temporal lobe, volumetry, **67**:135, **67**:155, **68**:65
third ventricle, schizophrenia, **67**:135
third ventricle, volumetry, **67**:135
volumetry, frontal lobe, **67**:203
volumetry, hippocampal formation, **67**:135
volumetry, limbic system, **67**:135
volumetry, schizophrenia, **67**:135, **67**:155
volumetry, striatum, **67**:155
volumetry, superior temporal gyrus, **67**:155
volumetry, temporal lobe, **67**:135, **67**:155
volumetry, third ventricle, **67**:135
white matter, childhood schizophrenia, **68**:77

Marijuana

basal ganglia, positron emission tomography, **67**:29
cerebellum, positron emission tomography, **67**:29
orbitofrontal cortex, positron emission tomography, **67**:29
positron emission tomography, basal ganglia, **67**:29
positron emission tomography, cerebellum, **67**:29
positron emission tomography, fluorodeoxyglucose, **67**:29
positron emission tomography, orbitofrontal cortex, **67**:29
tetrahydrocannabinol, positron emission tomography, substance abuse, **67**:29

Morphometrics

corpus callosum, image averaging, **67**:81
corpus callosum, magnetic resonance imaging, **67**:81
corpus callosum, shape analysis, **67**:81
image analysis, neuroanatomic landmarks, **67**:81
image averaging, magnetic resonance imaging, **67**:81
magnetic resonance imaging, corpus callosum, **67**:81
magnetic resonance imaging, image averaging, **67**:81
magnetic resonance imaging, neuroanatomic landmarks, **67**:81, **67**:145
magnetic resonance imaging, schizophrenia, **67**:81
magnetic resonance imaging, shape analysis, **67**:81
neuroanatomic landmarks, magnetic resonance imaging, **67**:81, **67**:145
schizophrenia, corpus callosum, **67**:81
schizophrenia, magnetic resonance imaging, **67**:81
schizophrenia, neuroanatomic landmarks, **67**:81

Neuropathology

caudate nucleus, schizophrenia, **68**:87, **68**:99
caudate nucleus, volume, **68**:87
glia cells, schizophrenia, **68**:99
glia cells, striatum, **68**:99
neuron number, schizophrenia, **68**:99
neuron number, striatum, **68**:99
nucleus accumbens, neuron number, **68**:99
nucleus accumbens, schizophrenia, **68**:87, **68**:99
nucleus accumbens, volume, **68**:87
putamen, neuron number, **68**:99
putamen, schizophrenia, **68**:87, **68**:99
putamen, volume, **68**:87
schizophrenia, caudate nucleus, **68**:87, **68**:99
schizophrenia, glia cells, **68**:99
schizophrenia, neuron number, **68**:99
schizophrenia, nucleus accumbens, **68**:87, **68**:99
schizophrenia, putamen, **68**:87, **68**:99
schizophrenia, striatum, **68**:87, **68**:99
striatum, neuron number, **68**:99

striatum, schizophrenia, **68**:87, **68**:99
striatum, volume, **68**:87

Neuropsychology

abstinence, alcohol abuse, **67**:99
abstinence, Raven's progressive-matrices, **67**:99
abstinence, single photon emission computed tomography, **67**:99
alcohol abuse, abstinence, **67**:99
alcohol abuse, Raven's progressive-matrices, **67**:99
alcohol abuse, single photon emission computed tomography, **67**:99
Alzheimer's Disease, cerebral blood flow, **68**:133
Alzheimer's Disease, longitudinal course, **68**:133
Alzheimer's Disease, single photon emission computed tomography, **68**:133
cerebral blood flow, Alzheimer's Disease, **68**:133
cerebral blood flow, longitudinal course, **68**:133
iodoamphetamine, single photon emission computed tomography, **67**:99
Raven's progressive-matrices, abstinence, **67**:99
Raven's progressive-matrices, alcohol abuse, **67**:99
Raven's progressive-matrices, single photon emission computed tomography, **67**:99
single photon emission computed tomography, abstinence, **67**:99
single photon emission computed tomography, alcohol abuse, **67**:99
single photon emission computed tomography, Alzheimer's Disease, **68**:133
single photon emission computed tomography, cerebral blood flow, **68**:133
single photon emission computed tomography, iodoamphetamine, **67**:99
single photon emission computed tomography, Raven's progressive-matrices, **67**:99
single photon emission computed tomography, smoking, **67**:99
single photon emission computed tomography, Tc-hexamethylpropyleneamine oxime, **68**:133
smoking, single photon emission computed tomography, **67**:99

Orbitofrontal cortex

marijuana intoxication, positron emission tomography, **67**:29
marijuana intoxication, tetrahydrocannabinol, **67**:29
positron emission tomography, fluorodeoxyglucose, **67**:29
positron emission tomography, marijuana intoxication, **67**:29
positron emission tomography, substance abuse, **67**:29
positron emission tomography, tetrahydrocannabinol, **67**:29
substance abuse, positron emission tomography, **67**:29
tetrahydrocannabinol, positron emission tomography, **67**:29

Panic disorder

electroencephalography, magnetic resonance imaging, **68**:41
electroencephalography, multilead mapping, **68**:31
magnetic resonance imaging, electroencephalography, **68**:41
magnetic resonance imaging, septohippocampal system, **68**:41
septohippocampal system, magnetic resonance imaging, **68**:41

Parietal lobe

attention, positron emission tomography, **67**:17
attention, posttraumatic stress disorder, **67**:17
attention, substance abuse, **67**:17
continuous performance test, positron emission tomography, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
continuous performance test, substance abuse, **67**:17
positron emission tomography, attention, **67**:17
positron emission tomography, continuous performance test, **67**:17
positron emission tomography, posttraumatic stress disorder, **67**:17
positron emission tomography, substance abuse, **67**:17
posttraumatic stress disorder, attention, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, positron emission tomography, **67**:17
substance abuse, attention, **67**:17
substance abuse, continuous performance test, **67**:17
substance abuse, positron emission tomography, **67**:17

Positron emission tomography

age, altanserin, **68**:11
age, cerebellum, **67**:71
age, dementia, **67**:71
age, dopamine, **67**:11
age, frontal cortex, **67**:71
age, methylspiroperidol, **67**:11
age, multi-infarct dementia, **67**:71
age, raclopride, **67**:11
age, receptor binding, **67**:11, **68**:11
age, receptor number, **68**:11
age, serotonin, **68**:11
age, striatum, **67**:11
age, wandering behavior, **67**:71
altanserin, age, **68**:11
altanserin, receptor binding, **68**:11
altanserin, receptor number, **68**:11
altanserin, serotonin, **68**:11
attention, cerebral blood flow, **67**:17
attention, parietal cortex, **67**:17
attention, posttraumatic stress disorder, **67**:17
attention, substance abuse, **67**:17
basal ganglia, marijuana intoxication, **67**:29
cerebellum, age, **67**:71
cerebellum, dementia, **67**:71
cerebellum, marijuana intoxication, **67**:29
cerebellum, multi-infarct dementia, **67**:71
cerebellum, substance abuse, **67**:29
cerebellum, tetrahydrocannabinol, **67**:29
cerebellum, wandering behavior, **67**:71
clozapine, dopamine, **67**:1

clozapine, frontal cortex, **67**:1
clozapine, receptor binding, **67**:1
clozapine, serotonin, **67**:1
clozapine, striatum, **67**:1
continuous performance test, parietal cortex, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
continuous performance test, substance abuse, **67**:17
dementia, cerebellum, **67**:71
dementia, frontal cortex, **67**:71
dementia, wandering behavior, **67**:71
dopamine, age, **67**:11
dopamine, clozapine, **67**:1
dopamine, frontal cortex, **67**:1
dopamine, haloperidol, **67**:163
dopamine, methylspiperone, **67**:159
dopamine, methylspiroperidol, **67**:11
dopamine, raclopride, **67**:11, **67**:163
dopamine, receptor binding, **67**:1, **67**:11, **67**:155, **67**:159, **67**:163
dopamine, schizophrenia, **67**:155, **67**:159, **67**:163
dopamine, striatum, **67**:1, **67**:11, **67**:155, **67**:163
fluorodeoxyglucose, age, **67**:71
fluorodeoxyglucose, basal ganglia, **67**:29
fluorodeoxyglucose, cerebellum, **67**:29, **67**:71
fluorodeoxyglucose, dementia, **67**:71
fluorodeoxyglucose, frontal cortex, **67**:71
fluorodeoxyglucose, marijuana intoxication, **67**:29
fluorodeoxyglucose, multi-infarct dementia, **67**:71
fluorodeoxyglucose, orbitofrontal cortex, **67**:29
fluorodeoxyglucose, substance abuse, **67**:29
fluorodeoxyglucose, tetrahydrocannabinol, **67**:29
fluorodeoxyglucose, wandering behavior, **67**:71
frontal cortex, age, **67**:71
frontal cortex, clozapine, **67**:1
frontal cortex, dementia, **67**:71
frontal cortex, dopamine, **67**:1
frontal cortex, multi-infarct dementia, **67**:71
frontal cortex, serotonin, **67**:1
frontal cortex, wandering behavior, **67**:71
haloperidol, dopamine, **67**:163
haloperidol, raclopride, **67**:163
haloperidol, schizophrenia, **67**:163
haloperidol, striatum, **67**:163
marijuana intoxication, basal ganglia, **67**:29
marijuana intoxication, cerebellum, **67**:29
marijuana intoxication, orbitofrontal cortex, **67**:29
methylspiperone, dopamine receptor binding, **67**:159
methylspiperone, schizophrenia, **67**:159
methylspiroperidol, age, **67**:11
methylspiroperidol, dopamine receptor binding, **67**:11
methylspiroperidol, raclopride, **67**:11
methylspiroperidol, striatum, **67**:11
multi-infarct dementia, cerebellum, **67**:71
multi-infarct dementia, frontal cortex, **67**:71
multi-infarct dementia, wandering behavior, **67**:71
orbitofrontal cortex, marijuana intoxication, **67**:29
orbitofrontal cortex, substance abuse, **67**:29
orbitofrontal cortex, tetrahydrocannabinol, **67**:29
parietal cortex, attention, **67**:17
parietal cortex, continuous performance test, **67**:17
parietal cortex, posttraumatic stress disorder, **67**:17
parietal cortex, substance abuse, **67**:17
posttraumatic stress disorder, attention, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, parietal cortex, **67**:17
posttraumatic stress disorder, substance abuse, **67**:17
raclopride, age, **67**:11
raclopride, dopamine receptor binding, **67**:11, **67**:163
raclopride, schizophrenia, **67**:163
raclopride, striatum, **67**:11, **67**:163
receptor binding, age, **67**:11, **68**:11
receptor binding, altanserin, **68**:11
receptor binding, clozapine, **67**:1
receptor binding, dopamine, **67**:1, **67**:11, **67**:155, **67**:159, **67**:163
receptor binding, frontal cortex, **67**:1
receptor binding, haloperidol, **67**:163
receptor binding, methylspiperone, **67**:159
receptor binding, methylspiroperidol, **67**:11
receptor binding, raclopride, **67**:11, **67**:163
receptor binding, schizophrenia, **67**:155, **67**:159, **67**:163
receptor binding, serotonin, **67**:1,
receptor binding, striatum, **67**:1, **67**:11, **67**:155, **67**:163
receptor loss with age, altanserin, **68**:11
receptor loss with age, serotonin, **68**:11
reliability, dopamine receptor binding, **67**:163
schizophrenia, dopamine, **67**:155, **67**:159, **67**:163
schizophrenia, haloperidol, **67**:163
schizophrenia, methylspiperone, **67**:159
schizophrenia, raclopride, **67**:163
schizophrenia, receptor binding, **67**:155, **67**:159, **67**:163
schizophrenia, striatum, **67**:155, **67**:163
schizophrenia, temporal lobe, **68**:111
schizophrenia, violence, **68**:111
serotonin, **68**:11
serotonin, age, **68**:11
serotonin, altanserin, **68**:11
serotonin, clozapine, **67**:1
serotonin, frontal cortex, **67**:1
serotonin, receptor binding, **67**:1, **68**:11
serotonin, receptor loss with age, **68**:11
striatum, age, **67**:11
striatum, dopamine, **67**:1, **67**:11, **67**:155, **67**:163
striatum, haloperidol, **67**:163
striatum, methylspiroperidol, **67**:11
striatum, raclopride, **67**:11, **67**:163
striatum, receptor binding, **67**:1, **67**:11, **67**:155, **67**:163
striatum, schizophrenia, **67**:155, **67**:163
substance abuse, basal ganglia, **67**:29
substance abuse, cerebellum, **67**:29
substance abuse, orbitofrontal cortex, **67**:29
substance abuse, attention, **67**:17
substance abuse, continuous performance test, **67**:17
substance abuse, parietal cortex, **67**:17
temporal lobe, schizophrenia, **68**:111
temporal lobe, violence, **68**:111

tetrahydrocannabinol, basal ganglia, **67**:29
tetrahydrocannabinol, cerebellum, **67**:29
tetrahydrocannabinol, orbitofrontal cortex, **67**:29
violence, schizophrenia, **68**:111
violence, temporal lobe, **68**:111
wandering behavior, age, **67**:71
wandering behavior, cerebellum, **67**:71
wandering behavior, dementia, **67**:71
wandering behavior, frontal cortex, **67**:71
wandering behavior, multi-infarct dementia, **67**:71

Posttraumatic stress disorder

attention, parietal cortex, positron emission tomography, **67**:17
continuous performance test, parietal cortex, positron emission tomography, **67**:17
parietal cortex, attention, continuous performance test, **67**:17
parietal cortex, positron emission tomography, **67**:17
positron emission tomography, attention, continuous performance test, **67**:17
positron emission tomography, parietal cortex, **67**:17

Putamen

age, iron content, **68**:55
age, magnetic resonance imaging, **68**:55
iron content, age, **68**:55
iron content, magnetic resonance imaging, **68**:55
magnetic resonance imaging, age, **68**:55
magnetic resonance imaging, iron content, **68**:55

Risperidone

basal ganglia, dopamine, **68**:23
basal ganglia, iodobenzamide, receptor binding, **68**:23
basal ganglia, obsessive-compulsive disorder, schizophrenia, **68**:23
basal ganglia, single photon emission computed tomography, **68**:23
dopamine, basal ganglia, **68**:23
dopamine, iodobenzamide, **68**:23
dopamine receptor binding, obsessive-compulsive disorder, schizophrenia, **68**:23
dopamine, single photon emission computed tomography, **68**:23
iodobenzamide, dopamine receptor binding, obsessive-compulsive disorder, schizophrenia, **68**:23
iodobenzamide, single photon emission computed tomography, **68**:23
obsessive-compulsive disorder, basal ganglia, **68**:23
obsessive-compulsive disorder, iodobenzamide, dopamine receptor binding, **68**:23
obsessive-compulsive disorder, single photon emission computed tomography, **68**:23
schizophrenia, basal ganglia, **68**:23
schizophrenia, iodobenzamide, dopamine receptor binding, **68**:23
schizophrenia, single photon emission computed tomography, **68**:23
single photon emission computed tomography, basal ganglia, **68**:23
single photon emission computed tomography, iodobenzamide, dopamine receptor binding, **68**:23
single photon emission computed tomography, obsessive-compulsive disorder, schizophrenia, **68**:23

Schizophrenia

age, corpus callosum, **68**:77
age, magnetic resonance imaging, **67**:189, **68**:77
age, temporal lobe, **67**:189
age of onset, magnetic resonance imaging, **67**:189, **68**:65, **68**:77
age of onset, temporal lobe, **67**:189, **68**:65
basal ganglia, dopamine receptor binding, **68**:23
basal ganglia, iodobenzamide, **68**:23
basal ganglia, risperidone, **68**:23
basal ganglia, single photon emission computed tomography, **68**:23
benzodiazepine receptor distribution, single photon emission computed tomography, **68**:125
caudate nucleus, neuron number, **68**:99
caudate nucleus, neuropathology, **68**:87, **68**:99
caudate nucleus, volume, **68**:87
childhood schizophrenia, corpus callosum, **68**:77
childhood schizophrenia, magnetic resonance imaging, **68**:77
computed tomography, frontal cortex, **67**:123
computed tomography, sulcal prominence, **67**:123
computed tomography, ventricle-brain ratio, **67**:123
corpus callosum, childhood age of onset, **68**:77
corpus callosum, magnetic resonance imaging, **67**:81, **68**:77
diazepam binding, single photon emission computed tomography, **68**:125
dopamine, basal ganglia, **68**:23
dopamine, haloperidol, **67**:163
dopamine, iodobenzamide, **68**:23
dopamine, methylspiperone, **67**:159
dopamine, raclopride, **67**:163
dopamine, receptor binding, positron emission tomography, **67**:155, **67**:159, **67**:163
dopamine, risperidone, **68**:23
dopamine, single photon emission computed tomography, **68**:23
dopamine, striatum, **67**:155, **67**:163
frontal cortex, computed tomography, **67**:123
frontal cortex, positive and negative symptoms, **67**:49
frontal cortex, single photon emission computed tomography, **67**:49
frontal lobe, benzodiazepine receptor distribution, **68**:125
frontal lobe, diazepam binding, **68**:125
frontal lobe, positive and negative symptoms, **68**:1
frontal lobe, single photon emission computed tomography, **68**:1, **68**:125
gamma-aminobutyric acid, single photon emission computed tomography, **68**:125
glia cells, neuropathology, schizophrenia, **68**:99
haloperidol, dopamine, **67**:163

haloperidol, positron emission tomography, **67**:163
haloperidol, raclopride, **67**:163
haloperidol, striatum, **67**:163
hippocampal formation, magnetic resonance imaging, **67**:135
hippocampal formation, negative symptoms, **67**:135
hippocampal formation, volumetry, **67**:135
iodobenzamide, basal ganglia, **68**:23
iodobenzamide, dopamine, **68**:23
iodobenzamide, receptor binding, **68**:23
iodobenzamide, risperidone, **68**:23
iodobenzamide, single photon emission computed tomography, **68**:23
limbic system, magnetic resonance imaging, **67**:135
limbic system, negative symptoms, **67**:135
limbic system, volumetry, **67**:135
magnetic resonance imaging, age, **67**:189
magnetic resonance imaging, age of onset, **67**:189, **68**:77
magnetic resonance imaging, childhood schizophrenia, **68**:77
magnetic resonance imaging, corpus callosum, **67**:81, **68**:77
magnetic resonance imaging, hippocampal formation, **67**:135
magnetic resonance imaging, limbic system, **67**:135
magnetic resonance imaging, morphometrics, **67**:81
magnetic resonance imaging, negative symptoms, **67**:135
magnetic resonance imaging, neuroanatomic landmarks, **67**:81
magnetic resonance imaging, striatum, **67**:155
magnetic resonance imaging, superior temporal gyrus, **67**:155
magnetic resonance imaging, temporal lobe, **67**:135, **67**:155, **67**:189, **68**:65
magnetic resonance imaging, third ventricle, **67**:135
magnetic resonance imaging, volumetry, **67**:135, **67**:155, **68**:65
magnetic resonance imaging, white matter, **68**:77
methylspiperone, dopamine, **67**:159
methylspiperone, positron emission tomography, **67**:159
methylspiperone, receptor binding, **67**:159
morphometrics, corpus callosum, **67**:81
morphometrics, magnetic resonance imaging, **67**:81
morphometrics, neuroanatomic landmarks, **67**:81
negative symptoms, frontal lobe, **67**:49, **68**:1
negative symptoms, hippocampal formation, **67**:135
negative symptoms, limbic system, **67**:135
negative symptoms, magnetic resonance imaging, **67**:135
negative symptoms, principal component analysis, **67**:49
negative symptoms, single photon emission computed tomography, **67**:49, **68**:1
negative symptoms, temporal lobe, **67**:49, **67**:135, **68**:1
negative symptoms, third ventricle, **67**:135
negative symptoms, volumetry, **67**:135
neuroanatomic landmarks, magnetic resonance imaging, **67**:81
neuroanatomic landmarks, morphometrics, **67**:81
neuron number, neuropathology, **68**:99
neuron number, striatum, **68**:99
neuropathology, caudate nucleus, **68**:87, **68**:99
neuropathology, glia cells, **68**:99
neuropathology, neuron number, **68**:99
neuropathology, nucleus accumbens, **68**:87, **68**:99
neuropathology, putamen, **68**:87, **68**:99
neuropathology, striatum, **68**:87, **68**:99
nucleus accumbens, neuropathology, **68**:87, **68**:99
nucleus accumbens, volume, **68**:87
positive symptoms, frontal lobe, **67**:49, **68**:1
positive symptoms, principal component analysis, **67**:49
positive symptoms, single photon emission computed tomography, **67**:49, **68**:1
positive symptoms, temporal lobe, **67**:49, **68**:1
positron emission tomography, dopamine, **67**:155, **67**:159, **67**:163
positron emission tomography, haloperidol, **67**:163
positron emission tomography, methylspiperone, **67**:159
positron emission tomography, raclopride, **67**:163
positron emission tomography, receptor binding, **67**:155, **67**:159, **67**:163
positron emission tomography, striatum, **67**:155, **67**:163
positron emission tomography, temporal lobe, **68**:111
positron emission tomography, violence, **68**:111
principal component analysis, positive and negative symptoms, **67**:49
putamen, neuropathology, **68**:87, **68**:99
putamen, volume, **68**:87
raclopride, dopamine receptor binding, **67**:163
raclopride, haloperidol, **67**:163
raclopride, positron emission tomography, **67**:163
raclopride, striatum, **67**:163
risperidone, basal ganglia, dopamine receptor binding, **68**:23
risperidone, iodobenzamide, **68**:23
risperidone, single photon emission computed tomography, **68**:23
single photon emission computed tomography, basal ganglia, **68**:23
single photon emission computed tomography, benzodiazepine receptor distribution, **68**:125
single photon emission computed tomography, diazepam binding, **68**:125
single photon emission computed tomography, dopamine, **68**:23
single photon emission computed tomography, frontal lobe, **67**:49, **68**:1, **68**:125
single photon emission computed tomography, iodobenzamide, **68**:23
single photon emission computed tomography, iomazenil uptake, **68**:125
single photon emission computed tomography, positive and negative symptoms, **67**:49, **68**:1
single photon emission computed tomography, receptor binding, **68**:23
single photon emission computed tomography, risperidone, **68**:23
striatum, dopamine receptor binding, **67**:155, **67**:163
striatum, glia cells, **68**:99
striatum, haloperidol, **67**:163
striatum, magnetic resonance imaging, **67**:155
striatum, neuron number, **68**:99
striatum, neuropathology, **68**:87, **68**:99
striatum, positron emission tomography, **67**:155, **67**:163
striatum, raclopride, **67**:163
striatum, volume, **68**:87
striatum, volumetry, **67**:155
sulcal prominence, computed tomography, **67**:123

superior temporal gyrus, magnetic resonance imaging, **67**:155
superior temporal gyrus, volumetry, **67**:155
temporal lobe, age, **67**:189
temporal lobe, age of onset, **67**:189
temporal lobe, magnetic resonance imaging, **67**:135, **67**:155, **67**:189, **68**:65
temporal lobe, negative symptoms, **67**:49, **67**:135, **68**:1
temporal lobe, positive symptoms, **67**:49, **68**:1
temporal lobe, positron emission tomography, **67**:155, **68**:111
temporal lobe, single photon emission computed tomography, **67**:49, **68**:1
temporal lobe, violence, **68**:111
temporal lobe, volumetry, **67**:135, **67**:155, **68**:65
third ventricle, magnetic resonance imaging, **67**:135
third ventricle, negative symptoms, **67**:135
third ventricle, volumetry, **67**:135
ventricle-brain ratio, computed tomography, **67**:123
violence, positron emission tomography, **68**:111
violence, temporal lobe, **68**:111
white matter, childhood schizophrenia, **68**:77
white matter, magnetic resonance imaging, **68**:77

Serotonin

age, altanserin, receptor binding, **68**:11
age, positron emission tomography, **68**:11
age, receptor loss with age, **68**:11
altanserin, positron emission tomography, **68**:11
altanserin, receptor binding, **68**:11
altanserin, receptor loss with age, **68**:11
clozapine, dopamine receptor binding, **67**:1
clozapine, frontal cortex, striatum, **67**:1
clozapine, positron emission tomography, **67**:1
dopamine, clozapine, **67**:1
dopamine, frontal cortex, positron emission tomography, **67**:1
dopamine, receptor binding, striatum, **67**:1
frontal cortex, clozapine, positron emission tomography, **67**:1
frontal cortex, receptor binding, **67**:1
positron emission tomography, age, **68**:11
positron emission tomography, altanserin, **68**:11
positron emission tomography, clozapine, **67**:1
positron emission tomography, dopamine, **67**:1
positron emission tomography, frontal cortex, **67**:1
positron emission tomography, receptor binding, **67**:1, **68**:11
positron emission tomography, receptor loss with age, **68**:11
positron emission tomography, striatum, **67**:1
striatum, clozapine, **67**:1
striatum, dopamine receptor binding, **67**:1
striatum, positron emission tomography, **67**:1

Single photon emission computed tomography

abstinence, alcohol abuse, **67**:99
abstinence, iodoamphetamine, **67**:99
abstinence, neuropsychology, **67**:99
abstinence, Raven's progressive-matrices, **67**:99
abstinence, substance abuse, **67**:99
affective disorder, age, **67**:59
affective disorder, frontal lobe, **67**:59, **68**:1, **68**:143
affective disorder, temporal lobe, **67**:59, **68**:1
age, affective disorder, **67**:59
age, frontal cortex, **67**:59
age, temporal lobe, **67**:59
alcohol abuse, abstinence, **67**:99
alcohol abuse, neuropsychology, **67**:99
alcohol abuse, Raven's progressive-matrices, **67**:99
Alzheimer's Disease, cerebral blood flow, **68**:133
Alzheimer's Disease, longitudinal course, **68**:133
Alzheimer's Disease, neuropsychological tests, **68**:133
basal ganglia, dopamine, **68**:23
basal ganglia, iodobenzamide, **68**:23
basal ganglia, obsessive-compulsive disorder, **68**:23
basal ganglia, receptor binding, **68**:23
basal ganglia, risperidone, **68**:23
basal ganglia, schizophrenia, **68**:23
benzodiazepine receptor distribution, schizophrenia, **68**:125
diazepam binding, benzodiazepine receptor distribution, **68**:125
diazepam binding, schizophrenia, **68**:125
dopamine, basal ganglia, **68**:23
dopamine, iodobenzamide, **68**:23
dopamine, obsessive-compulsive disorder, **68**:23
dopamine, receptor binding, **68**:23
dopamine, risperidone, **68**:23
dopamine, schizophrenia, **68**:23
frontal lobe, affective disorder, **67**:59, **68**:1, **68**:143
frontal lobe, benzodiazepine receptor distribution, schizophrenia, **68**:125
frontal lobe, diazepam binding, schizophrenia, **68**:125
frontal lobe, geriatric depression, **67**:59
frontal lobe, positive and negative symptoms, **67**:49, **68**:1
frontal lobe, schizophrenia, **67**:49, **68**:1, **68**:125
gamma-aminobutyric acid, benzodiazepine receptor distribution, schizophrenia, **68**:125
gamma-aminobutyric acid, diazepine binding, schizophrenia, **68**:125
gamma-aminobutyric acid, schizophrenia, **68**:125
geriatric depression, frontal cortex, **67**:59
geriatric depression, temporal lobe, **67**:59
graphical analysis, cerebral blood flow, **68**:143
heroin, opiate withdrawal, **67**:39
iodoamphetamine, substance abuse, **67**:99
iodobenzamide, basal ganglia, **68**:23
iodobenzamide, dopamine, **68**:23
iodobenzamide, obsessive-compulsive disorder, **68**:23
iodobenzamide, receptor binding, **68**:23
iodobenzamide, risperidone, **68**:23
iodobenzamide, schizophrenia, **68**:23
iomazenil uptake, schizophrenia, **68**:125
negative symptoms, frontal lobe, **67**:49, **68**:1
negative symptoms, positive symptoms, **67**:49, **68**:1
negative symptoms, principal component analysis, **67**:49
negative symptoms, schizophrenia, **67**:49, **68**:1
negative symptoms, temporal lobe, **67**:49, **68**:1
neuropsychological tests, Alzheimer's Disease, **68**:133
neuropsychology, alcohol abuse, **67**:99
neuropsychology, Raven's progressive-matrices, **67**:99
neuropsychology, substance abuse, **67**:99

obsessive-compulsive disorder, basal ganglia, **68**:23
obsessive-compulsive disorder, dopamine, **68**:23
obsessive-compulsive disorder, iodobenzamide, **68**:23
obsessive-compulsive disorder, receptor binding, **68**:23
obsessive-compulsive disorder, risperidone, **68**:23
opiate withdrawal, heroin, **67**:39
positive symptoms, frontal lobe, **67**:49, **68**:1
positive symptoms, negative symptoms, **67**:49, **68**:1
positive symptoms, principal component analysis, **67**:49
positive symptoms, schizophrenia, **67**:49, **68**:1
positive symptoms, temporal lobe, **67**:49, **68**:1
Raven's progressive-matrices, alcohol abuse, **67**:99
Raven's progressive-matrices, substance abuse, **67**:99
receptor binding, basal ganglia, **68**:23
receptor binding, dopamine, **68**:23
receptor binding, iodobenzamide, **68**:23
receptor binding, obsessive-compulsive disorder, **68**:23
receptor binding, risperidone, **68**:23
receptor binding, schizophrenia, **68**:23
risperidone, basal ganglia, **68**:23
risperidone, dopamine, **68**:23
risperidone, iodobenzamide, **68**:23
risperidone, obsessive-compulsive disorder, **68**:23
risperidone, receptor binding, **68**:23
risperidone, schizophrenia, **68**:23
schizophrenia, basal ganglia, **68**:23
schizophrenia, benzodiazepine receptor distribution, **68**:125
schizophrenia, diazepam binding, **68**:125
schizophrenia, dopamine, **68**:23
schizophrenia, frontal lobe, **67**:49, **68**:1, **68**:125
schizophrenia, gamma-aminobutyric acid, **68**:125
schizophrenia, iodobenzamide, **68**:23
schizophrenia, iomazenil uptake
schizophrenia, positive and negative symptoms, **67**:49, **68**:1
schizophrenia, risperidone, **68**:23
schizophrenia, temporal lobe, **67**:49, **68**:1
smoking, alcohol abuse, **67**:99
smoking, substance abuse, **67**:99
substance abuse, opiate withdrawal, **67**:39
substance abuse, neuropsychology, **67**:99
substance abuse, Raven's progressive-matrices, **67**:99
substance abuse, smoking, **67**:99
Tc-hexamethylpropyleneamine oxime, affective disorder, **67**:59, **68**:1, **68**:143
Tc-hexamethylpropyleneamine oxime, age, **67**:59
Tc-hexamethylpropyleneamine oxime, Alzheimer's Disease, **68**:133
Tc-hexamethylpropyleneamine oxime, frontal lobe, **67**:49, **67**:59, **68**:1, **68**:143
Tc-hexamethylpropyleneamine oxime, geriatric depression, **67**:59
Tc-hexamethylpropyleneamine oxime, heroin withdrawal, **67**:39
Tc-hexamethylpropyleneamine oxime, schizophrenia, **67**:49, **68**:1
Tc-hexamethylpropyleneamine oxime, substance abuse, **67**:39
Tc-hexamethylpropyleneamine oxime, temporal lobe, **67**:49, **67**:59, **68**:1
temporal lobe, affective disorder, **67**:59, **68**:1
temporal lobe, age, **67**:59
temporal lobe, geriatric depression, **67**:59
temporal lobe, positive and negative symptoms, **67**:49, **68**:1
temporal lobe, schizophrenia, **67**:49, **68**:1

Striatum

age, dopamine, **67**:11
age, methylspiroperidol, **67**:11
age, positron emission tomography, **67**:11
age, raclopride, **67**:11
age, receptor binding, **67**:11
caudate nucleus, neuropathology, **68**:87, **68**:99
caudate nucleus, schizophrenia, **68**:87, **68**:99
caudate nucleus, volume, **68**:87
clozapine, dopamine receptor binding, **67**:1
clozapine, positron emission tomography, **67**:1
clozapine, serotonin, **67**:1
dopamine, age, **67**:11
dopamine, clozapine, **67**:1
dopamine, haloperidol, **67**:163
dopamine, magnetic resonance imaging, **67**:155
dopamine, methylspiroperidol, **67**:11
dopamine, positron emission tomography, **67**:1, **67**:11, **67**:155, **67**:163
dopamine, raclopride, **67**:11, **67**:163
dopamine, receptor binding, **67**:1, **67**:11, **67**:155, **67**:163
dopamine, schizophrenia, **67**:155, **67**:163
glia cells, neuropathology, **68**:99
glia cells, schizophrenia, **68**:99
haloperidol, dopamine receptor binding, **67**:163
haloperidol, positron emission tomography, **67**:163
haloperidol, raclopride, **67**:163
haloperidol, schizophrenia, **67**:163
methylspiroperidol, age, **67**:11
methylspiroperidol, dopamine, **67**:11
methylspiroperidol, positron emission tomography, **67**:11
methylspiroperidol, receptor binding, **67**:11
neuron number, caudate nucleus, **68**:99
neuron number, neuropathology, **68**:99
neuron number, nucleus accumbens, **68**:99
neuron number, putamen, **68**:99
neuron number, schizophrenia, **68**:99
neuropathology, caudate nucleus, **68**:87, **68**:99
neuropathology, glia cells, **68**:99
neuropathology, neuron number, **68**:99
neuropathology, nucleus accumbens, **68**:87, **68**:99
neuropathology, putamen, **68**:87, **68**:99
neuropathology, schizophrenia, **68**:87, **68**:99
nucleus accumbens, neuron number, **68**:99
nucleus accumbens, neuropathology, **68**:87, **68**:99
nucleus accumbens, schizophrenia, **68**:87, **68**:99
nucleus accumbens, volume, **68**:87
positron emission tomography, age, **67**:11
positron emission tomography, clozapine, **67**:1
positron emission tomography, dopamine receptor binding, **67**:1, **67**:11, **67**:155, **67**:163
positron emission tomography, haloperidol, **67**:163
positron emission tomography, methylspiroperidol, **67**:11
positron emission tomography, raclopride, **67**:11, **67**:163

positron emission tomography, schizophrenia, **67**:155, **67**:163
putamen, neuron number, **68**:99
putamen, neuropathology, **68**:87, **68**:99
putamen, schizophrenia, **68**:87, **68**:99
putamen, volume, **68**:87
raclopride, age, **67**:11
raclopride, dopamine, **67**:11, **67**:163
raclopride, haloperidol, **67**:163
raclopride, positron emission tomography, **67**:11 **67**:163
raclopride, schizophrenia, **67**:163
schizophrenia, caudate nucleus, **68**:87, **68**:99
schizophrenia, dopamine, **67**:155, dopamine, **67**:163
schizophrenia, glia cells, **68**:99
schizophrenia, haloperidol, **67**:163
schizophrenia, neuron number, **68**:99
schizophrenia, neuropathology, **68**:87, **68**:99
schizophrenia, nucleus accumbens, **68**:87, **68**:99
schizophrenia, positron emission tomography, **67**:155, **67**:163
schizophrenia, putamen, **68**:87, **68**:99
schizophrenia, raclopride, **67**:163
volume, caudate nucleus, **68**:87
volume, nucleus accumbens, **68**:87
volume, putamen, **68**:87

Substance abuse/dependence

alcohol abuse, abstinence, **67**:99
alcohol abuse, neuropsychology, **67**:99
alcohol abuse, Raven's progressive-matrices, **67**:99
alcohol abuse, single photon emission computed tomography, **67**:99
alcohol abuse, smoking, **67**:99
attention, continuous performance test, **67**:17
attention, parietal cortex, **67**:17
attention, positron emission tomography, **67**:17
attention, posttraumatic stress disorder, **67**:17
basal ganglia, marijuana intoxication, **67**:29
basal ganglia, positron emission tomography, **67**:29
basal ganglia, tetrahydrocannabinol, **67**:29
cerebellum, marijuana intoxication, **67**:29
cerebellum, positron emission tomography, **67**:29
cerebellum, tetrahydrocannabinol, **67**:29
continuous performance test, parietal cortex, **67**:17
continuous performance test, positron emission tomography, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
cortical disinhibition, lysergic acid diethylamide, **67**:173
electroencephalography, cortical disinhibition, **67**:173
electroencephalography, lysergic acid diethylamide, **67**:173
evoked potentials, lysergic acid diethylamide, **67**:173
hallucinogen, perceptual disorder, **67**:173
heroin, single photon emission computed tomography, **67**:39
iodoamphetamine, single photon emission computed tomography, **67**:99
lysergic acid diethylamide, cortical disinhibition, **67**:173
lysergic acid diethylamide, electroencephalography, **67**:173
lysergic acid diethylamide, evoked potentials, **67**:173
lysergic acid diethylamide, perceptual disorder, **67**:173
marijuana intoxication, basal ganglia, cerebellum, orbitofrontal cortex, **67**:29
marijuana intoxication, positron emission tomography, **67**:29
neuropsychology, alcohol abuse, **67**:99
neuropsychology, single photon emission computed tomography, **67**:99
opiate withdrawal, single photon emission computed tomography, **67**:39
orbitofrontal cortex, marijuana intoxication, **67**:29
orbitofrontal cortex, positron emission tomography, **67**:29
orbitofrontal cortex, tetrahydrocannabinol, **67**:29
parietal cortex, attention, **67**:17
parietal cortex, continuous performance test, **67**:17
parietal cortex, positron emission tomography, **67**:17
parietal cortex, posttraumatic stress disorder, **67**:17
perceptual disorder, lysergic acid diethylamide, **67**:173
positron emission tomography, attention, **67**:17
positron emission tomography, basal ganglia, cerebellum, **67**:29
positron emission tomography, continuous performance test, **67**:17
positron emission tomography, marijuana intoxication, **67**:29
positron emission tomography, orbitofrontal and parietal cortex, **67**:29
positron emission tomography, posttraumatic stress disorder, **67**:17
positron emission tomography, tetrahydrocannabinol, **67**:29
posttraumatic stress disorder, attention, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, parietal cortex, **67**:17
posttraumatic stress disorder, positron emission tomography, **67**:17
Raven's progressive-matrices, alcohol abuse, **67**:99
Raven's progressive-matrices, single photon emission computed tomography, **67**:99
single photon emission computed tomography, alcohol abuse, abstinence, **67**:99
single photon emission computed tomography, heroin, **67**:39
single photon emission computed tomography, iodoamphetamine, **67**:99
single photon emission computed tomography, neuropsychology, **67**:99
single photon emission computed tomography, opiate withdrawal, **67**:39
single photon emission computed tomography, Raven's progressive-matrices, **67**:99
single photon emission computed tomography, smoking, **67**:99
single photon emission computed tomography, Tc-hexamethylpropyleneamine oxime, **67**:39
smoking, single photon emission computed tomography, **67**:99
tetrahydrocannabinol, basal ganglia, cerebellum, orbitofrontal cortex, **67**:29
tetrahydrocannabinol, positron emission tomography, **67**:29

Temporal lobe

affective disorder, age, **67**:59
affective disorder, single photon emission computed tomography, **67**:59, **68**:1
age, affective disorder, **67**:59

age, magnetic resonance imaging, **67**:189
age, schizophrenia, **67**:189
age, single photon emission computed tomography, **67**:59
age of onset, schizophrenia, **67**:189, **68**:65
Alzheimer's disease, magnetic resonance imaging, **68**:65
geriatric depression, single photon emission computed tomography, **67**:59
hippocampal formation, limbic system, **67**:135
hippocampal formation, magnetic resonance imaging, **67**:135
hippocampal formation, negative symptoms, **67**:135
hippocampal formation, schizophrenia, **67**:135
hippocampal formation, volumetry, **67**:135
limbic system, magnetic resonance imaging, **67**:135
limbic system, negative symptoms, **67**:135
limbic system, schizophrenia, **67**:135
limbic system, volumetry, **67**:135
magnetic resonance imaging, age, **67**:189
magnetic resonance imaging, hippocampal formation, **67**:135
magnetic resonance imaging, limbic system, **67**:135
magnetic resonance imaging, negative symptoms, **67**:135
magnetic resonance imaging, schizophrenia, **67**:135, **67**:155, **67**:189, **68**:65
magnetic resonance imaging, superior temporal gyrus, **67**:155
magnetic resonance imaging, volumetry, **67**:135, **67**:155, **68**:65
negative symptoms, affective disorder, **68**:1
negative symptoms, hippocampal formation, **67**:135
negative symptoms, limbic system, **67**:135
negative symptoms, magnetic resonance imaging, **67**:135
negative symptoms, positive symptoms, **67**:49, **68**:1
negative symptoms, schizophrenia, **67**:49, **67**:135, **68**:1
negative symptoms, single photon emission computed tomography, **67**:49, **68**:1
positive symptoms, negative symptoms, **67**:49, **68**:1
positive symptoms, schizophrenia, **67**:49, **68**:1

positive symptoms, single photon emission computed tomography, **67**:49, **68**:1
positron emission tomography, violence, **68**:111
schizophrenia, age, **67**:189
schizophrenia, age of onset, **67**:189
schizophrenia, hippocampal formation, **67**:135
schizophrenia, limbic system, **67**:135
schizophrenia, magnetic resonance imaging, **67**:135, **67**:155, **67**:189, **68**:65
schizophrenia, negative symptoms, **67**:49, **67**:135, **68**:1
schizophrenia, positive symptoms, **67**:49, **68**:1
schizophrenia, positron emission tomography, **67**:155, **68**:111
schizophrenia, single photon emission computed tomography, **67**:49, **68**:1
schizophrenia, superior temporal gyrus, **67**:155
schizophrenia, temporal lobe length, **67**:189
schizophrenia, violence, **68**:111
schizophrenia, volumetry, **67**:135, **67**:155, **68**:65
single photon emission computed tomography, affective disorder, **67**:59, **68**:1
single photon emission computed tomography, age, **67**:59
single photon emission computed tomography, geriatric depression, **67**:59
single photon emission computed tomography, negative symptoms, **67**:49, **68**:1
single photon emission computed tomography, positive symptoms, **67**:49, **68**:1
single photon emission computed tomography, schizophrenia, **67**:49, **68**:1
superior temporal gyrus, magnetic resonance imaging, **67**:155
superior temporal gyrus, schizophrenia, **67**:155
superior temporal gyrus, volumetry, **67**:155
violence, positron emission tomography, **68**:111
violence, schizophrenia, **68**:111
volumetry, hippocampal formation, **67**:135
volumetry, limbic system, **67**:135
volumetry, magnetic resonance imaging, **67**:135, **67**:155
volumetry, negative symptoms, **67**:135
volumetry, schizophrenia, **67**:135, **67**:155
volumetry, superior temporal gyrus, **67**:155

Tetrahydrocannabinol. See Marijuana

Ventricle-brain ratio. See Computed tomography

Violence
positron emission tomography, schizophrenia, **68**:111
positron emission tomography, temporal lobe, **68**:111
schizophrenia, positron emission tomography, **68**:111
schizophrenia, temporal lobe, **68**:111
temporal lobe, positron emission tomography, **68**:111
temporal lobe, schizophrenia, **68**:111